

Contents

| | |
|--------------|----|
| Contributors | xi |
|--------------|----|

| | |
|---------|------|
| Preface | xiii |
|---------|------|

1. Use of Phage λ Regulatory Signals to Obtain Efficient Expression of Genes in *Escherichia coli*

ALLAN SHATZMAN, YEN-SEN HO, AND MARTIN ROSENBERG

| | |
|---|----|
| I. Introduction | 2 |
| II. Expression of Prokaryotic Gene Products | 2 |
| III. Expression of Eukaryotic Genes | 8 |
| References | 14 |

2. Multipurpose Expression Cloning Vehicles in *Escherichia coli*

YOSHIHIRO MASUI, JACK COLEMAN, AND MASAYORI INOUE

| | |
|--|----|
| I. Introduction | 15 |
| II. pIN-I Vectors | 17 |
| III. pIN-II Vectors | 21 |
| IV. pIN-III Vectors | 23 |
| V. pIM Vectors: High-Copy-Number Vectors | 24 |
| VI. pIC Vectors: Hybrid Expression Vectors | 26 |
| VII. Promoter-Proving Vectors | 28 |
| VIII. General Cloning Strategy | 30 |
| IX. Summary | 31 |
| References | 31 |

3. Molecular Cloning in *Bacillus subtilis*

DAVID DUBNAU

| | |
|----------------------------|----|
| I. Introduction | 33 |
| II. Plasmid Transformation | 34 |
| III. Plasmid Vectors | 36 |
| IV. Cloning Stratagems | 45 |

| | |
|-------------------------------|----|
| V. Expression of Cloned Genes | 47 |
| VI. Conclusions | 48 |
| References | 49 |

4. Developments in *Streptomyces* Cloning

MERVYN J. BIBB, KEITH F. CHATER, AND DAVID A. HOPWOOD

| | |
|--|----|
| I. Introduction | 54 |
| II. Vectors | 54 |
| III. Use of Tn5 in Relation to <i>Streptomyces</i> DNA | 66 |
| IV. Applications of DNA Cloning in <i>Streptomyces</i> | 67 |
| V. Concluding Remarks | 79 |
| References | 80 |

5. Vectors for High-Level, Inducible Expression of Cloned Genes in Yeast

JAMES R. BROACH, YU-YANG LI, LING-CHUAN CHEN WU, AND MAKKUNI JAYARAM

| | |
|--------------------------------|-----|
| I. Introduction | 84 |
| II. Materials and Methods | 85 |
| III. Results and Discussion | 87 |
| IV. Summary | 107 |
| Appendix: Plasmid Construction | 107 |
| References | 115 |

6. Genetic Engineering of Plants by Novel Approaches

JOHN D. KEMP

| | |
|--|-----|
| I. Introduction | 119 |
| II. Novel Approaches to Creating Genetic Diversity | 121 |
| III. Concluding Remarks | 113 |
| References | 134 |

7. λ SV2, a Plasmid Cloning Vector that Can Be Stably Integrated in *Escherichia coli*

BRUCE H. HOWARD AND MAX E. GOTTESMAN

| | |
|---------------------------|-----|
| I. Introduction | 138 |
| II. Materials and Methods | 138 |
| III. Results | 141 |
| IV. Discussion | 150 |
| References | 152 |

8. Construction of Highly Transmissible Mammalian Cloning Vehicles Derived from Murine Retroviruses

RICHARD C. MULLIGAN

| | |
|----------------------|-----|
| I. Introduction | 155 |
| II. General Strategy | 157 |

| | |
|--|-----|
| III. Construction of a Prototype Retrovirus Vector | 159 |
| IV. Rescue of Recombinant Genomes as Infectious Virus | 162 |
| V. Characteristics of Retrovirus-Mediated Transformation | 164 |
| VI. Useful Derivative Vectors | 167 |
| VII. Conclusions and Prospects | 170 |
| References | 172 |

9. Use of Retrovirus-Derived Vectors to Introduce and Express Genes in Mammalian Cells

ELI GILBOA

| | |
|---|-----|
| I. Introduction | 175 |
| II. Organization of the M-MuLV Genome | 176 |
| III. Use of Retrovirus Vectors to Study the Mechanism of Gene Expression of the M-MuLV Genome | 178 |
| IV. A General Transduction System Derived from the M-MuLV Genome | 181 |
| V. Summary and Prospects | 187 |
| References | 188 |

10. Production of Posttranslationally Modified Proteins in the SV40-Monkey Cell System

DEAN H. HAMER

| | |
|-----------------------------------|-----|
| I. Introduction | 191 |
| II. SV40 Late-Replacement Vectors | 192 |
| III. Human Growth Hormone | 193 |
| IV. Hepatitis B Surface Antigen | 200 |
| V. Conclusions and Prospects | 207 |
| References | 209 |

11. Adenovirus Type 5 Region-E1A Transcriptional Control Sequences

PATRICK HEARING AND THOMAS SHENK

| | |
|--|-----|
| I. Introduction | 211 |
| II. Deletion Mutations in the 5'-Flanking Sequences of Ad5 Region E1A | 213 |
| III. Analysis of Mutagenized Templates in Cell-Free Transcription Extracts | 214 |
| IV. Analysis of Cytoplasmic E1A mRNAs Found <i>in Vivo</i> after Infection with Deletion Mutants | 216 |
| V. 5'-End Analyses of E1A mRNAs Synthesized <i>in Vivo</i> after Infection with Deletion Mutants | 218 |
| VI. E1A Transcriptional Control Region and Comparison to Other Eukaryotic Control Regions | 219 |
| References | 222 |

12. Expression of Proteins on the Cell Surface Using Mammalian Vectors

JOE SAMBROOK AND MARY-JANE GETHING

- I. How Proteins Are Normally Expressed on Mammalian Cell Surfaces 226
- II. Why It Would Be Useful to Express Proteins on the Surface of the Mammalian Cell 228
- III. Hemagglutinin of Influenza Virus Is the Best-Characterized Integral Membrane Protein 229
- IV. The Gene Coding for Hemagglutinin Is of Simple Structure 232
- V. Vector Systems 233
- VI. Hemagglutinin Is Efficiently Expressed from Both the Early and Late SV40 Promoters 237
- VII. Small-t Intron Leads to Genetic Instability of the Early-Replacement Vector 238
- VIII. Hemagglutinin Synthesized by SV40-HA Recombinants Is Biologically Active 240
- IX. Removing the C-Terminal Hydrophobic Sequence Converts Hemagglutinin from an Integral Membrane Protein to a Secreted Protein 242
- X. Prospects 243
- References 244

13. Expression of Human Interferon- γ in Heterologous Systems

RIK DERYNCK, RONALD A. HITZEMAN, PATRICK W. GRAY, AND DAVID V. GOEDEL

- I. Introduction 247
- II. Structure of the Human Interferon- γ cDNA 248
- III. Heterologous Expression in *Escherichia coli* 249
- IV. Expression in the Yeast *Saccharomyces cerevisiae* 251
- V. Conclusion 256
- References 257

14. Commercial Production of Recombinant DNA-Derived Products

J. PAUL BURNETT

- I. Introduction 259
- II. Production of Biosynthetic Human Insulin 261
- III. Other Pharmaceutical Applications of Recombinant DNA 272
- IV. Conclusion 276
- References 277

Appendix 1. Two-Dimensional DNA Electrophoretic Methods Utilizing *in Situ* Enzymatic Digestions

THOMAS YEE AND MASAYORI INOUE

| | |
|-----------------------------|-----|
| I. Introduction | 280 |
| II. Experimental Procedures | 280 |
| III. Examples | 283 |
| IV. Conclusion | 289 |
| References | 290 |

Appendix 2. Site-Specific Mutagenesis Using Synthetic Oligodeoxyribonucleotides as Mutagens

GEORGE P. VLASUK AND SUMIKO INOUE

| | |
|-----------------------------|-----|
| I. Introduction | 292 |
| II. Experimental Procedures | 293 |
| III. Example | 298 |
| IV. Conclusion | 301 |
| References | 302 |

| | |
|-------|-----|
| Index | 305 |
|-------|-----|